Peregrine Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $8.43M | Sell |
67,069
-5,903
| -8% | -$742K | 0.25% | 105 |
|
|
2025
Q1 | $8.07M | Buy |
72,972
+8,132
| +13% | +$899K | 0.27% | 100 |
|
|
2024
Q4 | $8.85M | Buy |
64,840
+1,159
| +2% | +$158K | 0.26% | 96 |
|
|
2024
Q3 | $7.34M | Sell |
63,681
-3,976
| -6% | -$458K | 0.22% | 124 |
|
|
2024
Q2 | $9.31M | Buy |
67,657
+881
| +1% | +$121K | 0.27% | 82 |
|
|
2024
Q1 | $9.21M | Sell |
66,776
-672
| -1% | -$92.7K | 0.26% | 93 |
|
|
2023
Q4 | $8.89M | Sell |
67,448
-11,625
| -15% | -$1.53M | 0.27% | 105 |
|
|
2023
Q3 | $8.9M | Sell |
79,073
-14,298
| -15% | -$1.61M | 0.27% | 133 |
|
|
2023
Q2 | $8.8M | Buy |
93,371
+8,754
| +10% | +$826K | 0.24% | 166 |
|
|
2023
Q1 | $8.56M | Buy |
84,617
+16,663
| +25% | +$1.69M | 0.25% | 178 |
|
|
2022
Q4 | $8.12M | Sell |
67,954
-17,780
| -21% | -$2.12M | 0.25% | 187 |
|
|
2022
Q3 | $9.11M | Sell |
85,734
-5,579
| -6% | -$593K | 0.29% | 144 |
|
|
2022
Q2 | $8.9M | Sell |
91,313
-72
| -0.1% | -$7.02K | 0.27% | 161 |
|
|
2022
Q1 | $8.57M | Sell |
91,385
-6,553
| -7% | -$614K | 0.2% | 202 |
|
|
2021
Q4 | $8.34M | Buy |
+97,938
| New | +$8.34M | 0.17% | 225 |
|